Cargando…

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series

SIMPLE SUMMARY: Focal radiation necrosis of the brain (fRNB) is a late side effect that can occur after treatment of brain lesions with focal radiation therapy (stereotactic radiosurgery [SRS] or stereotactic radiation therapy [SRT]). This is becoming more common as more cancer patients are receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tijtgat, Jens, Calliauw, Evan, Dirven, Iris, Vounckx, Manon, Kamel, Randa, Vanbinst, Anne Marie, Everaert, Hendrik, Seynaeve, Laura, Van Den Berge, Dirk, Duerinck, Johnny, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177060/
https://www.ncbi.nlm.nih.gov/pubmed/37174026
http://dx.doi.org/10.3390/cancers15092560
_version_ 1785040548716871680
author Tijtgat, Jens
Calliauw, Evan
Dirven, Iris
Vounckx, Manon
Kamel, Randa
Vanbinst, Anne Marie
Everaert, Hendrik
Seynaeve, Laura
Van Den Berge, Dirk
Duerinck, Johnny
Neyns, Bart
author_facet Tijtgat, Jens
Calliauw, Evan
Dirven, Iris
Vounckx, Manon
Kamel, Randa
Vanbinst, Anne Marie
Everaert, Hendrik
Seynaeve, Laura
Van Den Berge, Dirk
Duerinck, Johnny
Neyns, Bart
author_sort Tijtgat, Jens
collection PubMed
description SIMPLE SUMMARY: Focal radiation necrosis of the brain (fRNB) is a late side effect that can occur after treatment of brain lesions with focal radiation therapy (stereotactic radiosurgery [SRS] or stereotactic radiation therapy [SRT]). This is becoming more common as more cancer patients are receiving effective systemic therapy for brain metastases, extending survival, and putting them at risk for fRNB. Currently, treatment options are limited to long-term corticosteroid therapy, which has significant side effects, or surgery with its inherent risks. Bevacizumab, a monoclonal antibody that targets the vascular endothelial growth (VEGF), is effective in treating fRNB but its use has remained limited due to its cost. In this single-center case series, a fixed low dose of bevacizumab (400 mg loading dose followed by 100 mg every 4 weeks) was shown to be a safe and cost-effective alternative treatment option for fRNB. ABSTRACT: Focal radiation necrosis of the brain (fRNB) is a late adverse event that can occur following the treatment of benign or malignant brain lesions with stereotactic radiation therapy (SRT) or stereotactic radiosurgery (SRS). Recent studies have shown that the incidence of fRNB is higher in cancer patients who received immune checkpoint inhibitors. The use of bevacizumab (BEV), a monoclonal antibody that targets the vascular endothelial growth factor (VEGF), is an effective treatment for fRNB when given at a dose of 5–7.5 mg/kg every two weeks. In this single-center retrospective case series, we investigated the effectiveness of a low-dose regimen of BEV (400 mg loading dose followed by 100 mg every 4 weeks) in patients diagnosed with fRNB. A total of 13 patients were included in the study; twelve of them experienced improvement in their existing clinical symptoms, and all patients had a decrease in the volume of edema on MRI scans. No clinically significant treatment-related adverse effects were observed. Our preliminary findings suggest that this fixed low-dose regimen of BEV can be a well-tolerated and cost-effective alternative treatment option for patients diagnosed with fRNB, and it is deserving of further investigation.
format Online
Article
Text
id pubmed-10177060
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101770602023-05-13 Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series Tijtgat, Jens Calliauw, Evan Dirven, Iris Vounckx, Manon Kamel, Randa Vanbinst, Anne Marie Everaert, Hendrik Seynaeve, Laura Van Den Berge, Dirk Duerinck, Johnny Neyns, Bart Cancers (Basel) Article SIMPLE SUMMARY: Focal radiation necrosis of the brain (fRNB) is a late side effect that can occur after treatment of brain lesions with focal radiation therapy (stereotactic radiosurgery [SRS] or stereotactic radiation therapy [SRT]). This is becoming more common as more cancer patients are receiving effective systemic therapy for brain metastases, extending survival, and putting them at risk for fRNB. Currently, treatment options are limited to long-term corticosteroid therapy, which has significant side effects, or surgery with its inherent risks. Bevacizumab, a monoclonal antibody that targets the vascular endothelial growth (VEGF), is effective in treating fRNB but its use has remained limited due to its cost. In this single-center case series, a fixed low dose of bevacizumab (400 mg loading dose followed by 100 mg every 4 weeks) was shown to be a safe and cost-effective alternative treatment option for fRNB. ABSTRACT: Focal radiation necrosis of the brain (fRNB) is a late adverse event that can occur following the treatment of benign or malignant brain lesions with stereotactic radiation therapy (SRT) or stereotactic radiosurgery (SRS). Recent studies have shown that the incidence of fRNB is higher in cancer patients who received immune checkpoint inhibitors. The use of bevacizumab (BEV), a monoclonal antibody that targets the vascular endothelial growth factor (VEGF), is an effective treatment for fRNB when given at a dose of 5–7.5 mg/kg every two weeks. In this single-center retrospective case series, we investigated the effectiveness of a low-dose regimen of BEV (400 mg loading dose followed by 100 mg every 4 weeks) in patients diagnosed with fRNB. A total of 13 patients were included in the study; twelve of them experienced improvement in their existing clinical symptoms, and all patients had a decrease in the volume of edema on MRI scans. No clinically significant treatment-related adverse effects were observed. Our preliminary findings suggest that this fixed low-dose regimen of BEV can be a well-tolerated and cost-effective alternative treatment option for patients diagnosed with fRNB, and it is deserving of further investigation. MDPI 2023-04-29 /pmc/articles/PMC10177060/ /pubmed/37174026 http://dx.doi.org/10.3390/cancers15092560 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tijtgat, Jens
Calliauw, Evan
Dirven, Iris
Vounckx, Manon
Kamel, Randa
Vanbinst, Anne Marie
Everaert, Hendrik
Seynaeve, Laura
Van Den Berge, Dirk
Duerinck, Johnny
Neyns, Bart
Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title_full Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title_fullStr Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title_full_unstemmed Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title_short Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
title_sort low-dose bevacizumab for the treatment of focal radiation necrosis of the brain (frnb): a single-center case series
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177060/
https://www.ncbi.nlm.nih.gov/pubmed/37174026
http://dx.doi.org/10.3390/cancers15092560
work_keys_str_mv AT tijtgatjens lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT calliauwevan lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT dirveniris lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT vounckxmanon lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT kamelranda lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT vanbinstannemarie lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT everaerthendrik lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT seynaevelaura lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT vandenbergedirk lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT duerinckjohnny lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries
AT neynsbart lowdosebevacizumabforthetreatmentoffocalradiationnecrosisofthebrainfrnbasinglecentercaseseries